ArticlePloS one2014

Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

Jimson W D'Souza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.